Common side effects include joint pain, diarrhea, heartburn, nausea, and muscle pains. The collaborative atorvastatin diabetes study cards, comparing treatment with atorvastatin lipitor, pfizer inc with placebo in 2800 patients with type 2 diabetes but without overt heart. Stroke prediction and stroke prevention with atorvastatin. Safety of atorvastatin in the collaborative atorvastatin. For the prevention of cardiovascular disease, statins are a firstline treatment. Primary prevention of cardiovascular disease with atorvastatin in. Mar 01, 2009 the collaborative atorvastatin diabetes study cards was a doubleblind, randomized, placebocontrolled, multicenter trial of atorvastatin 10 mgday for the primary prevention of cvd in type 2 diabetes. We previously reported that allocation to atorvastatin 10 mg daily to 2838 patients with type 2 diabetes and no prior cardiovascular disease was associated with a 48% reduction in stroke risk in the collaborative atorvastatin diabetes study cards in the context of an average reduction in ldl cholesterol of 1. Jun 22, 2009 therefore, the first aim of this article is to report the effect of atorvastatin on albuminuria and estimated gfr gfr in one of the largest randomized trials n 2,838 of statin therapy in people with diabetes. An overview of cards collaborative atorvastatin diabetes. Atorvastatin reduced major cardiovascular disease events. An overview of cards collaborative atorvastatin diabetes study primary prevention of cardiovascular disease with atorvastatin in type 2.
Pdf primary prevention of cardiovascular disease with. The collaborative atorvastatin diabetes study cards is the first randomized controlled trial that assessed the effectiveness and safety of using atorvastatin in patients with type 2 diabetes with no prior history of cardiovascular disease. It received ethical approval both centrally and at each participating institution and each patient gave written informed consent. Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes. Safety of atorvastatin in the collaborative atorvastatin diabetes study cards the safety and efficacy of sta the safety and efficacy of statins for cvd prevention is well established, yet some physicians have concerns about the longterm safety of this class. Thus, atorvastatin has a potential role in the primary prevention of cardiovascular events in diabetic patients at risk of chd, irrespective of pretreatment ldlcholesterol levels. The collaborative atorvastatin diabetes study cards.
Atorvastatin reduced major cardiovascular disease events in type 2 diabetes mellitus colhoun hm, betteridge dj, durrington pn, et al. To describe baseline characteristics of patients in the. Abstract background there are few data on the role of lipid lowering in the primary prevention of coronary heart disease chd in diabetic. In the collaborative atorvastatin diabetes study cards, treatment with atorvastatin 10 mg compared. Collaborative atorvastatin diabetes study american. To estimate the costeffectiveness of atorvastatin 10 mg compared with no treatment for the primary prevention of. Atorvastatin reduced major cardiovascular disease events in. Objective diabetesassociated autoantibodies can be detected in adultonset diabetes, even when initially noninsulin requiring, i. Development and validation of a model to predict absolute.
Design of the collaborative atorvastatin diabetes study. Atorvastatin 10 mg daily is safe and efficacious in reducing the risk of. Mar 26, 2002 methods the collaborative atorvastatin diabetes study cards is a multicentre, randomized, placebo. Collaborative atorvastatin diabetes study cards 2838 primary prevention patients no ascvd with type 2 diabetes at least 1 other cv risk factor such as smoking, hypertension, retinopathy, or microalbuminuria ldlc levels. Dec 01, 2007 we previously reported that allocation to atorvastatin 10 mg daily to 2838 patients with type 2 diabetes and no prior cardiovascular disease was associated with a 48% reduction in stroke risk in the collaborative atorvastatin diabetes study cards in the context of an average reduction in ldl cholesterol of 1. Collaborative atorvastatin diabetes study cards and fol lowed for 3. Department of medicine, royal free and university college medical. Lipidlowering statin therapy reduces the proportional risk as effectively in older patients as in younger individuals. Aim to describe baseline characteristics of patients in the collaborative atorvastatin diabetes study cards, a randomized, placebo.
Researchdesignand methodswe used a nested casecontrol design sampling all incident cases of cvd with available plasma and randomly selecting three control subjects, who were free of cvd throughout followup, per case. The aim of the collaborative atorvastatin diabetes. Patients with type 2 diabetes and no prior cvd n 2,838. The collaborative atorvastatin diabetes study cards is a multi. Oct 30, 2008 controversy surrounds whether the ratio of apolipoprotein b apob to apolipoprotein ai apoai is the best lipoprotein discriminator of chd risk in nondiabetic populations, but the issue has never been investigated in type 2 diabetes.
Cards was a doubleblind, randomised, placebocontrolled, multicentre trial of atorvastatin 10 mg daily in the primary prevention of cardiovascular disease in type 2 diabetes 1618. Last year, these investigators reported a 37% reduction in the primary outcome, a composite of acute coronary. Openurl1crossref2pubmed3web of science4 q in patients with type 2 diabetes mellitus, is atorvastatin better than. We aimed to identify adultonset autoimmune diabetes in patients with established type 2 diabetes participating in the collaborative atorvastatin diabetes study cards to characterize their phenotype and clinical. Stroke prediction and stroke prevention with atorvastatin in. The primary objective is to investigate whether treatment with the hydroxymethylglutaryl coenzyme a reductase inhibitor. Costeffectiveness of primary prevention of cardiovascular. Apolipoproteins, cardiovascular risk and statin response in. This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. A landmark lipitor study of patients with type 2 diabetes. We conducted a post hoc analysis to compare the efficacy and safety of atorvastatin among 1,129 patients aged 6575 years at randomization with 1,709 younger patients in the collaborative atorvastatin diabetes study cards. Colhoun hm1, betteridge dj, durrington pn, hitman ga, neil ha, livingstone sj, thomason mj, mackness mi, charltonmenys v, fuller jh. Among these studies 1422 are the heart protection study hps, 14 the collaborative atorvastatin diabetes study ca r ds, 15 the angloscandinavian cardiac outcomes lipid lowering arm ascotlla, 16 the antihypertensive and lipid lowering treatment to prevent heart. Data from the collaborative atorvastatin diabetes study cards were used colhoun et al.
In 2,627 participants without known vascular disease in the collaborative atorvastatin diabetes study, apob, apoai, ldlcholesterol ldlc and hdl. The collaborative atorvastatin diabetes study cards is the first large primary prevention study to focus specifically on the role of a statin in patients aged 4075 years with type 2 diabetes, but no signs or symptoms of preexisting vascular disease and who had only average or below average cholesterol levels. Costeffectiveness of primary prevention of cardiovascular disease. The goal of the collaborative atorvastatin diabetes study cards trial was to determine the effectiveness of the lipidlowering agent atorvastatin in reducing cardiovascular events and death among diabetic patients with at least one heart disease risk factor, but without elevated cholesterol. Objective rates of cardiovascular disease are highest in the elderly.
The safety and tolerability of atorvastatin 10 mg in the. Mar 05, 2012 ironically, there is a very compelling clinical trial showing the value of one statin, lipitor atorvastatin, in type 2 diabetes the collaborative atorvastatin diabetes study known as cards. Therefore, the first aim of this article is to report the effect of atorvastatin on albuminuria and estimated gfr gfr in one of the largest randomized trials n 2,838 of statin therapy in people with diabetes. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the collaborative atorvastatin diabetes study cards. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the collaborative atorvastatin diabetes study.
Aug 21, 2004 the aim of the collaborative atorvastatin diabetes study cards was to assess the effectiveness of 10 mg of atorvastatin daily versus placebo in the primary prevention of cardiovascular disease in patients with type 2 diabetes. The collaborative atorvastatin diabetes study cards was a doubleblind, randomized, placebocontrolled, multicenter trial of atorvastatin 10 mgday for the primary prevention of cvd in type 2 diabetes. Cost effectiveness of atorvastatin in patients with type 2. Apolipoproteins, cardiovascular risk and statin response. Dec 19, 2019 in the collaborative atorvastatin diabetes study cards, the effect of atorvastatin calcium on cardiovascular disease cvd endpoints was assessed in 2838 subjects 94% white, 68% male, ages 40 to 75 with type 2 diabetes based on who criteria, without prior history of cardiovascular disease and with ldl. The collaborative atorvastatin diabetes study cards randomized placebocontrolled trial. Pdf there are few data on the role of lipid lowering in the primary prevention of coronary heart disease chd in diabetic patients.
Collaborative atorvastatin diabetes study cards or card. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes cards overview 1 a multicenter randomized placebo controlled trial to determine hard outcomes of atorvastatin 10mg vs. The collaborative atorvastatin diabetes study cards randomised patients to either atorvastatin 10mg per day or to placebo. This and the adherence rate were from the collaborative atorvastatin diabetes study cards, a randomised controlled trial with a 3. The collaborative atorvastatin diabetes study cards is a multi centre, randomized, placebocontrolled, doubleblind clinical trial of primary prevention of cardiovascular disease in patients. Pdf baseline characteristics in the collaborative atorvastatin. Fenofibrate intervention and event lowering in diabetes. Ofthe collaborative atorvastatin diabetes study cards inthe belgian population marbaix s1,vandenberghe h1,van gaal l2 1p. Effect of highdose atorvastatin on renal function in. Besides evaluating global differences, the study also evaluated the effects in three patient risk groups within the trial. The trial was stopped 2 years earlier than planned because of significant benefit at the second interim analysis. Cards 2004 treatment comparison n target population entry lipid criteria primary endpoint atorvastatin 10mg vs.
Effects of atorvastatin on kidney outcomes and cardiovascular. Baseline characteristics in the collaborative atorvastatin. Collaborative atorvastatin diabetes study american college. A post hoc analysis of data from the collaborative atorvastatin diabetes study cards, a randomised, placebocontrolled trial of 2,838. The study received ethical approval both centrally and at each participating institution, and each patient gave written informed consent. Rapid emergence of effect of atorvastatin on cardiovascular. We aimed to identify adultonset autoimmune diabetes in patients with established type 2 diabetes participating in the collaborative atorvastatin diabetes study cards to characterize their phenotype and clinical outcome. The collaborative atorvastatin diabetes study cards is the first large primary prevention study to focus specifically on the role of a statin in patients aged 4075 years with type 2 diabetes, but no signs or symptoms of preexisting vascular disease and who had only. Ironically, there is a very compelling clinical trial showing the value of one statin, lipitor atorvastatin, in type 2 diabetes the collaborative atorvastatin diabetes study known as cards. Methods the collaborative atorvastatin diabetes study cards is a multicentre, randomized, placebo. In this trial, known as cards the collaborative atorvastatin diabetes study, atorvastatin had a similar tolerability profile to that of placebo. Collaborative atorvastatin diabetes study cards diabetes care. An overview of cards collaborative atorvastatin diabetes study.
An analysis from the collaborative atorvastatin diabetes study cards author links open overlay panel helen m. Atorvastatin reduced cv events even in low ldl dm patients. The aim of the collaborative atorvastatin diabetes study cards was to assess the effectiveness of 10 mg of atorvastatin daily versus placebo in the primary prevention of cardiovascular disease in patients with type 2 diabetes. Pdf design of the collaborative atorvastatin diabetes study. Current clinical practice is based on relatively few randomized, control trials. Design of the collaborative atorvastatin diabetes study cards. Collaborative atorvastatin diabetes study listed as cards. Atorvastatin, sold under the brand name lipitor among others, is a statin medication used to prevent cardiovascular disease in those at high risk and treat abnormal lipid levels. The objective of this study was to evaluate the safety and tolerability of atorvastatin 10 mg compared with placebo in 2,838 patients with type 2 diabetes and no history of coronary heart disease who were enrolled in the collaborative atorvastatin diabetes study cards and followed for 3. We conducted a post hoc analysis to compare the efficacy and safety of atorvastatin among 1,129 patients aged 6575 years. Subjects and methods a total of 2,838 patients, who were aged 40 to 75 years and had type 2 diabetes without a documented history of cardiovascular disease and without elevated ldlcholesterol, were recruited from 32 centres in the uk and ireland and randomly allocated to atorvastatin. In the collaborative atorvastatin diabetes study cards, the effect of atorvastatin calcium on cardiovascular disease cvd endpoints was assessed in 2838 subjects 94% white, 68% male, ages 40 to 75 with type 2 diabetes based on who criteria, without prior history of cardiovascular disease and with ldl.
1215 1384 1208 827 42 786 441 414 148 1515 495 956 1145 1077 1163 1466 845 298 1126 136 717 555 977 1595 1340 1279 1247 54 1356 395 297 428 265 1386 1011 1089 886 285 44 540 394 1044 572